ArticleJournal, genetic engineering & biotechnology2026
Molecular study of KIT gene that is related to drug resistance in chronic myeloid leukemia patients.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The KIT gene, known as proto-oncogene c-Kit, encodes a receptor tyrosine kinase and plays a crucial role in cellular processes through activation that initiates signal transduction pathways. The KIT protein includes five extracellular domains, a kinase domain, a transmembrane helix, and a juxta-membrane domain. The study investigated these domains in chronic myeloid leukemia (CML) patients, revealing insights that enhance clinical protocols for tyrosine kinase inhibitors used in targeted therapy for hematological malignancies. However, mutations in the kinase domain present challenges by impairing drug binding. In this exploratory investigation, mainly through PCR and Sanger sequencing techniques, 50 samples (30 patients and 20 controls) were utilized. A total of 27 mutations were identified. While the following mutations (G753C, G538C, A415T, and A404G) were the most frequent, (G814C, G858T, G876T, and G880A) were only found in control cohort. Interestingly, many unique mutations were detected in the Iraqi population, suggesting specific genetic polymorphisms. Furthermore, the data showed that younger patients had better responses to imatinib with fewer dangerous mutations, while middle-aged patients faced significant resistance, which correlated with weight gain and obesity. Elderly individuals displayed a higher mutation burden, necessitating multiple treatment changes. Despite limitations, this exploratory study stressed the importance of considering patients' genetic backgrounds and BMIs to improve therapeutic outcomes for CML patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.